Tybourne Capital Management HK Ltd. Sells 2,100 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Tybourne Capital Management HK Ltd. cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 150,790 shares of the medical research company’s stock after selling 2,100 shares during the quarter. IQVIA makes up 10.0% of Tybourne Capital Management HK Ltd.’s portfolio, making the stock its 5th largest position. Tybourne Capital Management HK Ltd. owned 0.08% of IQVIA worth $35,733,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in IQV. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter valued at $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA during the third quarter valued at $28,000. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the second quarter worth about $27,000. Finally, Itau Unibanco Holding S.A. acquired a new position in IQVIA during the 2nd quarter valued at about $29,000. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

Shares of NYSE IQV opened at $201.44 on Thursday. The company has a fifty day moving average price of $220.36 and a 200 day moving average price of $226.57. The firm has a market cap of $36.56 billion, a PE ratio of 26.44, a PEG ratio of 2.10 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. BTIG Research dropped their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Barclays dropped their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Truist Financial reduced their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Morgan Stanley decreased their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.